Baylor College of Medicine's Jessica Watts, Dr. Jerome Pollet, and Dr. Paul Ling with Tess. Photo by Jackelin Reyna/Houston Zoo

An innovative team from Baylor College of Medicine and Texas Children’s Hospital has worked with the Houston Zoo to develop a first-of-its-kind treatment for elephants, which has been administered to its first patient.

Tess, the beloved, 40-year-old matriarch of the Houston Zoo’s elephant herd, is recovering well after receiving the first-ever mRNA vaccine against elephant endotheliotropic herpesvirus (EEHV) 1A on Tuesday, June 18. The veterinary staff at the Houston Zoo will monitor Tess in the coming weeks to check her reaction and the efficacy of the vaccine.

EEHV 1A is a deadly infection for Asian Elephants. While generally benign in African Elephants, Asian Elephants can develop fatal hemorrhages. The fatality rate is a whopping 80 percent, making it one of the most serous threats to elephant populations outside of humans.

Anti-viral drugs have some effect on the disease, but two-thirds show no improvement. This has led to a search for a vaccine. For 15 years, the Houston Zoo and Dr. Paul Ling at Baylor College of Medicine’s Department of Virology and Microbiology have partnered to develop the drug. They have been helped by worldwide research from zoos and animal specialists, as well as graduate student Jessica Watts and Dr. Jeroen Pollet at Houston's Texas Children’s Hospital. The research has been funded by private donations, research partnerships, and grants.

Before being inoculated, the mRNA vaccine was exhaustively tested, with the dosage being extrapolated from data involving horses.

Houston Zoo veterinarians will periodically test Tess to see if she is developing the appropriate antibodies. If she is and there are no adverse reactions, the next step will be to administer the vaccine to the rest of the Houston herd. Many of these are Tess’s own children (Tucker, Tupelo, Tilly, and Teddy) and grandchildren (Winnie).

Should the vaccine prove effective, the doses will be made available worldwide to zoos and private elephant sanctuaries. It is likely to have a significant benefit on protecting and preserving the Asian Elephant population. As of January, there are fewer than 50,000 of the animas left in the wild. They are currently listed as endangered, and breeding programs and research done through the Houston Zoo are essential to keeping the animals from going extinct.

------

This article originally ran on CultureMap.

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

Drs. Maria Elena Bottazzi and Peter Hotez got the green light to distribute their low-cost COVID-19 vaccine in Indonesia. Photo courtesy

Houston doctors get approval for low-cost COVID vaccine abroad

green light

A Houston-born COVID-19 vaccine has gotten the go-ahead to be produced and distributed in Indonesia.

PT Bio Farma, which oversees government-owned pharmaceutical manufacturers in Indonesia, says it’s prepared to make 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses a year by 2024. This comes after the vaccine received authorization from the Indonesian Food and Drug Authority for emergency use in adults.

With more than 275 million residents, Indonesia is the world’s fourth most populous country.

IndoVac was created by the Texas Children’s Hospital Center for Vaccine Development and Baylor College of Medicine. Drs. Peter Hotez and Maria Elena Bottazzi lead the vaccine project. Bio Farma is licensing IndoVac from BCM Ventures, the commercial group at the Baylor College of Medicine.

“Access to vaccines in the developing world is critical to the eradication of this virus,” Hotez, co-director of the Texas Children’s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine at Baylor College of Medicine, says in a news release.

Aside from distributing the vaccine in Indonesia, Bio Farma plans to introduce it to various international markets.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” says Bottazzi, co-director of the Texas Children’s Hospital Center for Vaccine Development and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional [COVID-19] variants will develop, hindering the progress achieved by currently available vaccines in the United States and other Western countries.”

Bio Farma says it has completed Phase 1 and Phase 2 clinical trials for IndoVac and is wrapping up a Phase 3 trial.

IndoVac is a version of the patent-free, low-cost Corbevax vaccine, developed in Houston and dubbed “The World’s COVID-19 Vaccine.” The vaccine formula can be licensed by a vaccine producer in any low- or middle-income country, which then can take ownership of it, produce it, name it, and work with government officials to distribute it, Hotez told The Texas Tribune in February.

Among donors that have pitched in money for development of the vaccine are the Houston-based MD Anderson and John S. Dunn foundations, the San Antonio-based Kleberg Foundation, and Austin-based Tito’s Vodka.

“During 2022, we hope to partner with the World Health Organization and other United Nations agencies to vaccinate the world. We believe that global vaccine equity is finally at hand and that it is the only thing that can bring the COVID pandemic to an end,” Hotez and Bottazzi wrote in a December 2021 article for Scientific American.

Drs. Maria Elena Bottazzi and Peter Hotez at the Center for Vaccine Development. Photo courtesy of Texas Children's Hospital

2 Houston powerhouses deploy game-changing COVID-19 worldwide vaccine

a good shot

With the U.S. logging its highest single-day total of new COVID-19 cases (441,278 infections) and some 281, 808, 270 cases documented worldwide, new treatments worldwide are in major demand — especially in emerging nations.

To that end, Texas Children’s Hospital and Baylor College of Medicine announced a new COVID vaccine ready to deploy in India and soon, other underserved countries.

Corbevax, which is dubbed “The World’s COVID-19 Vaccine,” utilizes a traditional recombinant protein-based technology that will enable production at large scales, per a press release. That means the inoculation will be widely accessible to inoculate the global population.

This new vaccine was developed at Texas Children’s Hospital CVD and led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez — and in-licensed from BCM Ventures, Baylor College of Medicine’s integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

After completing two Phase III clinical trials involving more than 3000 subjects the vaccine was found to be safe, well tolerated, and immunogenic. Current research shows Corbevax notably effective against the Ancestral-Wuhan strain and the globally dominant Delta variant, press materials note.

Safe, streamlined, low-cost vaccines for middle- to low-income countries are central to the world’s fight against the COVID-19 pandemic, the two Houston organizations note. Indeed, without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries, per research.

“This announcement is an important first step in vaccinating the world and halting the pandemic,” said Hotez in a statement. “Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant. Widespread and global vaccination with our Texas Children’s-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow.”

------

This article originally ran on CultureMap.

Texas Children's Hospital and Baylor College of Medicine are working on a new COVID-19 vaccine candidate. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston health care organizations team up for the 'people's vaccine'

COVID Collaboration

Two major health care institutions in Houston — Texas Children's Hospital and the Baylor College of Medicine — are a step closer to rolling out what they dub the "people's vaccine" for COVID-19.

The two institutions, along with India-based vaccine and pharmaceutical company Biological E Ltd., have gained approval to move ahead this month with Phase III clinicals trials in India of a COVID-19 vaccine candidate called Corbevax. The Texas Children's Hospital Center for Vaccine Development developed the vaccine's protein antigen, which was licensed from the Baylor College of Medicine's BCM Ventures commercialization arm.

Unlike COVID-19 vaccines in the U.S., Corbevax contains the so-called "spike protein" from the surface of the novel coronavirus. Once that protein is injected via a vaccine, the body is supposed to begin building immunity against the protein and thereby prevent serious illness.

Experts envision Corbevax being a readily available weapon in the global fight against the COVID-19 pandemic, thanks to the simple vaccine platform (like the one used to prevent Hepatitis B) and the ability to store the vaccine in normal refrigerated settings. The targets of this vaccine are children and mothers.

"In the midst of India's public health crisis, it is our hope that our Texas Children's and Baylor COVID-19 vaccine can be released for emergency authorization in India and in all countries in need of essential COVID-19 vaccinations," Dr. Peter Hotez, co-director of the Texas Children's Hospital Center for Vaccine Development, says in a June 9 news release.

India has reported more than 29 million cases of COVID-19, causing 354,000 deaths. The country's COVID-19 surge reached its peak in May.

"The vaccines currently available cannot be manufactured quick enough to meet supply shortages in low-income countries," Hotez says. "Our vaccine is truly 'the people's vaccine,' created to serve the most marginalized and underserved populations that are hardest hit by this pandemic. This is the vaccine that could be used to vaccinate the world."

In the Phase III trial, the two-dose Corbevax vaccine will be administered to about 1,200 people age 18 to 80 at 15 sites in India. A larger global study of Corbevax is in the works.

According to India.com, Corbevax could be the most affordable COVID-19 vaccine available in the nation of nearly 1.37 billion people, costing close to $7 for a two-dose regimen. The Indian government already has preordered 300 million doses of Corbevax, which has shown promise in Phase I and Phase II trials. The Phase II trial ended in April.

If the Phase III trial goes as planned, doses could be widely administered as soon as August. Biological E initially plans to produce 75 million to 80 million doses per month, according to media reports. The Indian company foresees manufacturing at least 1 billion doses by the end of 2022.

ClassPass, which recently opened a Houston location, has launched a new tool for users to find their closest vaccine location. Photo courtesy of ClassPass

Tech company launches COVID-19 vaccine finder in Houston

there's an app for that

A global tech company that recently opened a local office in Houston has announced a major upgrade to its app — and it's now available in Houston.

ClassPass, a network of fitness and wellness partners, now has Houston vaccine centers searchable within the app and website. Members can find their closest vaccine center and get important information — like hours and address — as well as how to contact the locations; however, users aren't able to book directly through ClassPass.

"We are in a global health crisis and every company should be helping to support relief and vaccination efforts however they can. Using the ClassPass platform to connect members with vaccine centers is a natural extension of our technology and a way that we can contribute to curbing the spread of COVID-19," says Jeff Bladt, vice president of pricing and inventory, in a news release.

"We have deep knowledge of how to help people find accurate and up-to-date information on local businesses after routing millions of users to fitness and wellness locations across 30 countries," he adds.

Users can search for COVID vaccine locations online or through the app. Photo courtesy of ClassPass

The new search option has been rolled out already in in Austin and Dallas, as well as Boston, Chicago, Denver, Miami, New York City and Washington, D.C.

"The process of finding a vaccination appointment can be challenging and many people don't know where to start," says Dr. Vin Gupta, a critical care pulmonologist, health policy expert, and NBC News Medical Analyst, in the release.

"I was thrilled to hear that ClassPass, a high touch app that has already trained people how to search for vital health information, is leveraging their platform to make it easier to identify vaccine sites and secure appointments," he continues. "Anything that can address this information gap is critical in getting more people vaccinated."

ClassPass quickly pivoted when the pandemic hit last year, and now all 41,500 fitness, wellness, and beauty partners on the app have been asked to provide updated details on their COVID policies. ClassPass also worked with 5,000 top studios around the world to add digital classes as an option.

In March, Houston-based ClassPass exec, Rachel Moctron, joined the Houston Innovators Podcast to discuss this pivot and the new Houston office. Listen to it below.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Meet the 40+ finalists for the 2026 Houston Innovation Awards

The Top Startups

Editor's note: We are just days away from unveiling the winners of the 2026 Houston Innovation Awards. Before the big reveal, we've compiled all of the coverage of this year's finalists. Get to know the 40+ finalists for nine awards categories below, then stay tuned to InnovationMap.com, where we'll announce the winners on Wednesday, November 18.

Minority-founded Business Finalists 

Our Minority-founded Businesses category honors innovative Houston startups founded or co-founded by BIPOC or LGBTQ+ representation. Five minority-founded businesses have been named finalists for the 2026 award. The finalists range from an AI edtech startup to a company operating in the floating offshore energy infrastructure sector.

They are: AI Made Fun, Deep Anchor Solutions, HEXASpec, Prana Surgical, and Torres Orbital Mining Inc. Read more.

Female-founded Business Finalists

Houston is home to many standout female founders, making inroads and breakthroughs in every industry. Our Female-founded Business category honors women-led startups that are shaping Houston innovation. Five female-founded businesses have been named finalists for the 2026 award. The finalists range from an AI startup for C-Suite execs to a company developing semi-autonomous crawler robots for corrosion detection.

They are: Adair, ARIX Technologies, Bairitone Health, FlowCellutions, and ParaDocs Health. Read more.

Health Tech Business Finalists

Houston has been driving medical innovation for decades and the local healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for. The Health Tech Business category in our 2026 Houston Innovation Awards honors innovative startups within the health and medical technology sectors. Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

They are: Bairitone Health, InformAI Inc., Prana Surgical, and Skybound MedTech. Read more.

Deep Tech Business Finalists

Houston has long been at the forefront of innovation, from NASA’s Johnson Space Center to its startup ecosystem using technology to disrupt industries. Our Deep Tech Business category honors innovative startups providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics and space sectors. Five deep tech companies have been named finalists for the 2026 award.

They are: Casimir, FocisAI, Machine Saver Inc., Square Robot, and Venus Aerospace. Read more.

Energy Transition Business Finalists

Houston is home to a growing number of startups reshaping what it means to be called the "Energy Capital of the World." Our Energy Transition Business category honors those innovative startups that are providing solutions within renewables, climatetech, clean energy, alternative materials, circular economy, and more. Five clean energy startups have been named finalists for the 2026 award. The finalists range from a lower-emission steel producer to a diagnostics platform developer working to support batteries used in data centers.

They are: Capwell Services, FlowCellutions, Hertha Metals, Mars Materials, and Solidec. Read more.

Scaleup of the Year Finalists

From IPOs to groundbreakings, some of Houston's most innovative companies reached major milestones this year. Our Scaleup of the Year category honors innovative later-stage startups that have recently reached a significant milestone in company growth. Three scaleups have been named finalists for the 2026 award.

They are: Erock, Hertha Metals, and Venus Aerospace. Read more.

Incubator/Accelerator of the Year Finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward. Our Incubator/Accelerator of the Year category honors local organizations that are championing and fueling the growth of Houston startups. Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

They are: Activate, Impact Hub Houston, and MarMo Innovation. Read more.

Startup of the Year Finalists

Seven exceptional finalists are in the running for the title of Startup of the Year, which is our people's choice award in the annual Houston Innovation Awards. From innovative platforms benefiting the education, commerce, health, investment and IT sectors to next-gen memory technology and improvements for robotic supply chains, these startups are making an impact in Houston and beyond.

The finalists are: Fluxworks, IronLattice, Lumino, Progress Report, Rosarium Health, TokenRoster, and Thread. Read more.

Mentor of the Year Finalists

Houston’s thriving startup ecosystem is supported by a network of experienced leaders who work behind the scenes, investing their time and knowledge to help the next generation of entrepreneurs succeed. Our Mentor of the Year category honors those who dedicate their time and expertise to guide and support budding entrepreneurs. Six individuals have been named finalists for the 2026 award. They support promising startups in the medical tech, digital health, clean energy, hardware sectors and more.

They are: Al Danto, Rice University; Eric Rubenstein, New Climate Ventures; Jeremy Pitts, Activate; Joe Alapat, Liongard; Kyle Judah, Rice University's Liu Idea Lab for Innovation & Entrepreneurship; Rachel Bickham, Bickham Services Unlimited LLC. Read more.

Houston's new state-of-the-art academy FLAMA breaks ground at historic site

Groundbreaking Education

Houston’s newest school for arts and music broke ground in October in the city’s historic East End. The Frank Liu Jr. Academy for Music and Arts (FLAMA), a tuition-free charter school, will welcome students in pre-K through 8th grade next August.

Members of the Liu family, the school’s founding board members, elected officials, and East End community partners gathered at Buffalo Bayou Partnership’s historic Turkey Bend development for the official groundbreaking ceremony on October 8, which kicked off with a performance by the Kinder High School for the Performing and Visual Arts’ Mariachi group.

The new school is on a portion of the former Folgers Coffee Plant, located at 235 N. Norwood St. OMA, an international architectural firm known for its approach to urbanism, cultural projects, and adaptive reuse, is transforming the 1930s plant into a state-of-the-art educational facility.

“We’re excited to celebrate this milestone for FLAMA and look forward to seeing the transformation of the historic Folgers plant into a new home for music and arts education,” said Jason Long, one of the firm’s partners. “Like fine-tuning an instrument, our design recalibrates the existing industrial structure into an open, connected, and expressive environment for learning. FLAMA will be a new learning environment that builds on the character of the existing building while giving it new life for the community.”

Flama academy Courtesy rendering

Unfolding across three stories, the school draws inspiration from Montessori education principles, which prioritize openness, independence, and collective learning through shared “neighborhoods.”

It all begins when students, families and guests enter through a private courtyard. The welcoming space will change the building’s original industrial facade into a brightly colored, kid-friendly spot, complete with yellow and green blocks spelling out the school’s name. The original windows will be restored to preserve the building’s historic character and upgraded to meet contemporary energy standards. Similarly, all of the school’s classrooms are located around the building’s perimeter, providing an abundance of natural light.

Inside, FLAMA’s three stories are divided so that younger students will find their classrooms at the school’s base, and they will move upward through the school as they progress through grade levels. The ground level has a common area for younger kids that could host drum circles, movement classes, or “breakout play.”

Children in first and second grade have their own larger open space, with an eye-catching staircase, that's inspired by the curve of a French horn. The space lends itself to everything from small gatherings to performances by the school’s early musicians.

As students progress through third grade and up, they’ll find FLAMA’s upper floors created to meet their growing artistic and intellectual needs. One example is the open library, a shared spot for students in third through fifth grades. It has flexible furniture that can transform the space into a place for group study and project work, as well as one that can host after-school activities. Directly above this library is a second common room for middle schoolers where students in sixth, seventh, and eighth grades can study.

FLAMA academy Courtesy rendering

These two libraries are connected by an F-shaped floor opening that references both the F-hole of a string instrument and the forte symbol. Musicians know this curly f as a note indicating them to play a passage with strength. That could easily be a metaphor for the school itself, which will combine high-quality education with rigorous academics. This visual cue emphasizes FLAMA’s desire for music and art instruction to amplify learning across reading, writing, math, and science.

“This will be a place where children can discover their talents, families can find opportunities close to home, and music and art can open the doors to a stronger education,” said Congresswoman Sylvia Garcia, who attended the groundbreaking. “I know how much it matters when someone brings opportunity within the reach of a child.”

Dr. R. Scott Allen, FLAMA’s founding superintendent and former principal of Kinder HSPVA, spoke about the school’s vision to pair a rigorous, engaging academic opportunity with deep immersion in music and visual arts.

Congressman Christian Menefee, State Senator Carol Alvarado, and Houston City Councilmember Mario Castillo also delivered remarks at the ceremony, speaking about the school’s power to not only transform Houston’s Second, Third, and Fifth Ward communities, but also bring incredible education opportunities to students. Former Mayor Annise Parker, former State Board of Education Member Staci Childs, State Representative Christina Morales, and Houston City Councilmembers Joaquin Martinez and Sallie Alcorn also attended the event.

“In this city, known for our undeniable contributions to music and arts, the gap has never been ability or talent; it has always been opportunity, and opportunity can be built,” said Kirby Liu, who spoke at the groundbreaking, memorializing his late brother’s vision of arts education for the youngest Houstonians. “When it comes to opportunity being foreclosed on our children, we will try like hell to bust those damned doors down.”

The Frank Liu Jr. Foundation has pledged $20 million in financial support during FLAMA’s first years of operation. Applications are now open for kindergarten and first grade for the 2027-2028 school year.

---

This article first appeared on CultureMap.com.

New manufacturing facility breaks ground at NASA’s Johnson Space Center

making space

HITT Contracting has broken ground on NASA’s Applied Spaceflight Fabrication Facility (ASFF) at Johnson Space Center, the Washington, D.C.-based construction firm announced late last month.

The project, known as Building 70, will house a high-bay machine shop to support component production for future NASA space missions, according to HITT. The 37,625-square-foot building is the first part of a larger goal to create an engineering complex that unites assembly space, lab capabilities and manufacturing at JSC. It will consolidate machining equipment and operations that are currently spread across multiple campus buildings into one location.

The project broke ground in October at JSC’s Historic District. The Houston Business Journal reports construction is expected to wrap in August of 2028.

“This project will modernize facilities that support America’s space missions,” PJ Ross, chief financial officer at HITT, said in a LinkedIn post. “Proud of our team and partners as we begin construction that will advance aerospace testing and innovation.”

HITT Contracting is one of seven companies awarded infrastructure contracts by NASA earlier this year for work at JSC. According to NASA, the construction contracts “[support] up to $300 million in upgrades to mission‑support facilities, utilities, and equipment across the NASA Johnson campus.”

Construction Drive reports that HITT will also renovate Building 13 South on the JSC campus as part of the $300 million initiative.

“Building for precision manufacturing starts with understanding how the space needs to perform,” Todd Hudson, vice president at HITT Contracting, added in the release. “Our team brings the technical expertise and collaborative approach to deliver a facility that meets the Johnson Space Center’s needs today and supports the next generation of spaceflight innovation. We’re proud to continue our partnership with NASA.”

NASA also recently announced awards as part of its expanded Moon Base exploration, science and infrastructure capabilities. Houston-based Intuitive Machines and seven other spacetech companies, including SpaceX, Blue Origin and Firefly Aerospace, were selected to receive funding.

The awards are part of the next phase of NASA’s CLPS (Commercial Lunar Payload Services) initiative, which will grant the companies a combined total of up to $10 billion over 10 years.

Intuitive Machines and Webster-based MEI Technologies were also awarded contracts this past summer from NASA to develop robots for exploring the surface of Mars. Read more here.